NEO-ADJUVANT 177LU-PSMA-I&T RADIONUCLIDE IN HIGH-RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY: A FEASIBILITY TRIAL

被引：0
|
作者：
Frumer, Michael
Rosenbaum, Eli
Kedar, Daniel
Zohar, Yarden
Baniel, Jack
Steinmetz, Adam
Bernstine, Hanna
Groshar, David
Golan, Shay
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP15-20
引用
收藏
页码：E271 / E271
页数：1
相关论文
共 50 条
  • [41] Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer
    Nauseef, Jones T.
    Osborne, Joseph
    Gregos, Peter
    Thomas, Charlene
    Bissassar, Mahelia
    Singh, Sharon
    Patel, Amie
    Tan, Angela
    Naiz, Muhammad Obaid
    Zuloaga, Juana Martinez
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Nagar, Himanshu
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Neo-adjuvant PARP inhibition prior to prostatectomy: A phase II biomarker-driven trial for men with high-risk, localized prostate cancer and alterations in DNA repair genes.
    Dall'era, Marc
    McPherson, John
    Evans, Christopher P.
    Parikh, Mamta
    Verma, Rashmi
    Lara, Primo N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [43] 177Lu -PSMA-I&T PSMA radioligand therapy in metastatic castration - resistant prostate cancer: First clinical trial in Asia
    Bu, Ting
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S528
  • [44] A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
    Gruenwald, Viktor
    Fendler, Wolfgang P.
    Herrmann, Ken
    Reis, Henning
    Roghmann, Florian
    Rahbar, Kambiz
    Heidenreich, Axel
    Giesel, Frederik
    Niegisch, Guenter
    Hadaschik, Boris A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS352 - TPS352
  • [45] Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer
    Ravi, Praful
    Kwak, Lucia
    Devlies, Wout
    Xie, Wanling
    Chipidza, Fallon
    Yang, Xiaoyu
    Bubley, Glenn
    Kaplan, Irving
    Kibel, Adam S.
    Nguyen, Paul
    Taplin, Mary-Ellen
    PROSTATE, 2024, 84 (04): : 342 - 348
  • [46] Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).
    Ornstein, Moshe Chaim
    Stephenson, Andrew J.
    Elson, Paul
    Tyler, Allison Janine
    Profusek, Pam
    Grivas, Petros
    Rini, Brian I.
    Klein, Eric A.
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Phase 1 Trial of Neoadjuvant Radiation Therapy Before Prostatectomy for High-Risk Prostate Cancer
    Koontz, Bridget F.
    Quaranta, Brian P.
    Pura, John A.
    Lee, W. R.
    Vujaskovic, Zeljko
    Gerber, Leah
    Haake, Michael
    Anscher, Mitchell S.
    Robertson, Cary N.
    Polascik, Thomas J.
    Moul, Judd W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (01): : 88 - 93
  • [48] Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
    Eapen, Renu S.
    Buteau, James P.
    Jackson, Price
    Mitchell, Catherine
    Oon, Sheng F.
    Alghazo, Omar
    McIntosh, Lachlan
    Dhiantravan, Nattakorn
    Scalzo, Mark J.
    O'Brien, Jonathan
    Sandhu, Shahneen
    Azad, Arun A.
    Neeson, Scott G.
    Sharma, Gaurav
    Haskali, Mohammad B.
    Bressel, Mathias
    Chen, Kenneth
    Jenjitranant, Pocharapong
    McVey, Aoife
    Moon, Daniel
    Lawrentschuk, Nathan
    Neeson, Paul J.
    Murphy, Declan G.
    Hofman, Michael S.
    EUROPEAN UROLOGY, 2024, 85 (03) : 217 - 226
  • [49] Initial clinical outcomes of 177Lu-PSMA-I&T therapy in patients wit metastatic castration-resistant prostate cancer (mCRPC) - Singapore experience.
    Thang, Sue Ping
    Lam, Winnie Wing Chuen
    Tong, Aaron Kian Ti
    Yan, Xuexian
    Huang, Hian Liang
    Ng, David Chee Eng
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [50] Significance of interim 18F-PSMA-1007 PET/CT for early prediction of 177Lu-PSMA-I&T treatment effect in metastatic castration-resistant prostate cancer patients
    Cheung, S.
    Chen, S.
    Wong, Y.
    Yip, Y.
    Ho, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S178 - S179
12345